Page 15 - Resverlogix Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

Study Approval Paves the Way for Trial Participants to Begin Taking Apabetalone

Donald mccaffreyUniversity of albertaBiomedical panelHealth research ethics boardWorld health organizationDrug administrationHealth informationToronto stock exchangeResverlogix corpPostmedia network incHealth canadaResverlogix receives ethics approvalCanadian sitesApproval pavesTrial participantsBegin taking apabetalone

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada CALGARY, AB and CHICAGO — June 3, 2021 — Resverlogix Corp. ("Resverlogix") (TSX:RVX) and EVERSANA™, the pioneer of next.

United statesDonald mccaffreyJim langResverlogix corpToronto stock exchangePending launchInitial commercializationEmergency use authorizationNew drug applicationChief executive officerTherapy designationForward looking statementsAnnual information formஒன்றுபட்டது மாநிலங்களில்டொனால்ட் ம்க்க்யாஃப்‌ரீஜிம் லாங்

Shenzhen Hepalink Pharmaceutical Group Co , Ltd Acquires Additional Securities of Resverlogix Corp

Shenzhen Hepalink Pharmaceutical Group Co , Ltd Acquires Additional Securities of Resverlogix Corp
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Shenzhen hepalink pharmaceutical group co ltdResverlogix corpAlberta newsfile corpPrivate placementப்ரைவேட் வேலை வாய்ப்பு

Resverlogix s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo

Article content CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “ Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “ Novel Therapeutic Options for Cardiovascular Disease with CKD”. The publication can be viewed HERE, and the accompanying editorial HERE. “To my knowledge this is the first time that a cardiovascular risk reducing intervention – apabetalone – has shown such an improvement in clinical outcomes in patients with chronic kidney disease (CKD) – defined as an estimated glo

Reggio calabriaUnited statesFrancesca mallamaciDonald mccaffreyGrande ospedale metropolitanoCarmine zoccaliKam kalantar zadehResverlogix corpToronto stock exchangeUniversity of california irvineNephrology divisionBetonmace clinical steering committeeMajor adverse cardiovascular eventsChronic kidney diseaseRecent acute coronary syndromeClinical journal

Resverlogix s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease Resverlogix CorpApril 27, 2021 GMT CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “ Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial ”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “

Reggio calabriaUnited statesFrancesca mallamaciDonald mccaffreyGrande ospedale metropolitanoCarmine zoccaliKam kalantar zadehResverlogix corpToronto stock exchangeUniversity of california irvineNephrology divisionBetonmace clinical steering committeeMajor adverse cardiovascular eventsChronic kidney diseaseRecent acute coronary syndromeControlled trial